HLA-A and acute myeloid leukemia: The HLA-A*02:01-restricted TCR for CLAVEEVSL as well as AVEEVSLRK and CLAVEEVSL as HLA class I-binding dNPM1 peptides on primary AML are protected by patent publication number WO/2019/004831.